NCT03091257 2026-03-13A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaMassachusetts General HospitalPhase 1 Active not recruiting30 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02140840 2016-04-07UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibUniversity of ArkansasPhase 2 Withdrawn